Somnomed Limited (AU:SOM)
ASX:SOM
Want to see AU:SOM full AI Analyst Report?
SOM Stock Chart & Stats
AU$0.56
AU$0.03(6.67%)
At close: 4:00 PM EST
AU$0.56
AU$0.03(6.67%)
Day’s Range― - ―
52-Week RangeAU$0.50 - AU$0.95
Previous CloseN/A
Volume51.81K
Average Volume (3M)705.41K
Market Cap
AU$131.45M
Enterprise ValueAU$121.95M
Total Cash (Recent Filing)AU$18.03M
Total Debt (Recent Filing)AU$14.01M
Price to Earnings (P/E)―
Beta1.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,083,250
10 Day Avg. Volume159,446
30 Day Avg. Volume705,406
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside78.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth With Strong Gross MarginsSomnomed’s consistent revenue growth combined with a ~60% gross margin indicates durable product demand and manufacturing/pricing efficiency. Strong gross margins provide structural support for long-term profitability expansion if operating leverage and SG&A discipline improve.
Material Improvement In Cash GenerationA >562% rise in free cash flow and positive operating cash flow despite net losses shows the business generates real cash from operations. This cash cushion reduces refinancing risk, funds reinvestment or market expansion, and supports execution on strategic initiatives over the medium term.
Conservative Leverage ProfileLow debt-to-equity (0.17) implies financial flexibility and lower solvency risk, enabling Somnomed to invest in R&D, geographic expansion or absorb shocks without high interest burdens. This conservative capital structure is a durable strength while profitability is being restored.
Bears Say
Persistent Negative ProfitabilityOngoing net losses and negative EBIT margins mean Somnomed is not yet converting revenue into sustainable operating profit. Without a clear path to sustained positive margins, reliance on cash improvements may be fragile and limits the company’s ability to self-fund growth long term.
Negative Return On EquityA negative ROE signals that shareholders’ capital is not producing positive returns, reflecting operational inefficiencies or unprofitable investments. Persistently negative ROE can hinder investor confidence and makes capital raising more costly, constraining strategic options.
Concentrated Product And Revenue ModelHeavy reliance on a single product category and per-device sales via dental providers concentrates revenue and limits recurring income. This structural dependence increases exposure to reimbursement, regulatory or clinical-adoption shifts and slows revenue diversification over the medium term.
Somnomed Limited News
SOM FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest share price was AU$0.50 and its highest was AU$0.94 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is AU$131.45M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,083,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in AU:SOM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.28%
12-Months-Change
Fundamentals
Return on Equity
-5.31%
Trailing 12-Months
Asset Growth
14.75%
Trailing 12-Months
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. It offers SomnoDent, an oral appliance for obstructive sleep apnea; SomnoBrux, a dental guard for the treatment of teeth grinding damage; SomMorning Repositioner, which help return mandible back to its pre-treatment centric position; and SomTabs for cleaning oral devices. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
SOM Company Deck
SOM Earnings Call
Q2 2026
0:00 / 0:00
SOM Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(78.57% Upside)
Technical Analysis
Options Prices
Currently, No data available
---